Postmenopausal bleeding: why it needs prompt assessment

Postmenopausal bleeding is common enough to have a well-established clinical pathway, but it should never be dismissed as simply another hormonal fluctuation. Any vaginal bleeding that occurs after 12 consecutive months without a period warrants medical assessment, even if it is light, happens once or appears after sex.

Most cases are not caused by cancer. Menopausal changes can make vaginal and uterine tissues thinner and more fragile, while polyps and hormone therapy can also produce bleeding. The reason clinicians investigate promptly is that bleeding is the leading presenting symptom of endometrial, or womb, cancer. A UK team has now reported progress on a non-invasive test using urine and vaginal fluid that may help identify women at low risk and reduce unnecessary internal procedures.

Why postmenopausal bleeding happens

After menopause, lower estrogen levels can thin the vaginal lining and make it drier, less elastic and more vulnerable to small tears. This condition, part of the genitourinary syndrome of menopause, can cause spotting after sex or irritation. Thinning of the uterine lining can also lead to bleeding.

Other non-cancerous explanations include cervical or endometrial polyps, inflammation, infection and changes associated with medicines. Systemic menopausal hormone therapy can cause unscheduled bleeding, particularly during the first months of treatment or after a change in dose or regimen. Bleeding may also occur when doses are missed or estrogen and progestogen exposure are not adequately balanced.

None of these possibilities can be confirmed from the bleeding pattern alone. A small amount of pink or brown discharge can require the same initial attention as a heavier episode. Blood from the urinary or gastrointestinal tract can also be mistaken for vaginal bleeding, so establishing its source is part of the assessment.

How postmenopausal bleeding is assessed now

The first step usually includes a clinical history covering the timing and amount of bleeding, medications, HRT use and relevant health risks. An examination may identify vaginal thinning, cervical changes, polyps or another visible source.

Transvaginal ultrasound is commonly used to measure the thickness of the endometrium, the tissue lining the uterus. A thin, clearly visualised lining is generally reassuring, although thresholds and subsequent decisions depend on local guidance and individual circumstances. If the lining is thicker than expected, cannot be assessed adequately, or bleeding continues, clinicians may recommend an endometrial biopsy or hysteroscopy. Hysteroscopy uses a narrow camera to examine the uterine cavity and may allow a targeted sample or polyp removal.

These tests are effective, but internal ultrasound, biopsy and hysteroscopy can be uncomfortable or painful. They also use specialist time and resources. A reliable triage test that rules out cancer in lower-risk women could therefore improve both the experience and efficiency of care. Crucially, a new test would need to demonstrate very high sensitivity so that clinically important disease is not missed.

What the new womb cancer test could change

The test reported by UK researchers analyses urine and vaginal fluid samples from women who have experienced bleeding after menopause. Its intended role is not simply to diagnose cancer from a convenient sample. The more immediate aim is risk stratification: identifying women whose result is sufficiently reassuring that they may be able to avoid, or be deprioritised for, more invasive investigation.

That distinction matters. Early findings can be promising without establishing that a test is ready for routine care. Researchers must validate performance in larger, varied populations and determine how accurately it detects different stages and subtypes of endometrial cancer. They must also assess false-negative and false-positive results, laboratory reproducibility, cost and how the test performs alongside ultrasound and clinical risk factors.

Menopausal status, HRT use, ethnicity, body composition, diabetes and other factors may affect baseline risk or test performance. Evidence will also need to show whether the approach works equitably across these groups. Until validation and clinical adoption are complete, the test does not replace current referral and investigation pathways.

HRT can cause bleeding, but it should not be assumed to be the cause

Unscheduled bleeding is a recognised issue with menopausal hormone therapy. With continuous combined HRT, spotting can occur while the endometrium adjusts, especially in the first six months. Sequential regimens are designed to produce a predictable withdrawal bleed, but bleeding outside the expected window may still require review.

The timing of assessment depends on factors including when HRT began, whether the regimen changed, how persistent or heavy the bleeding is and the individual’s risk profile. New bleeding after a stable period without it deserves attention. So does bleeding that continues beyond the expected adjustment period, becomes heavier, occurs after sex or is accompanied by pelvic pain.

This does not mean HRT needs to be stopped automatically. A clinician may review adherence, doses, the type and route of estrogen, and whether progestogen is providing adequate endometrial protection. The correct response is structured assessment rather than either panic or reassurance based only on the fact that hormones are being used.

A bleeding record can sharpen the clinical picture

The practical message remains unchanged while less invasive testing is developed: bleeding after menopause should be reported promptly. Recording the date, duration, approximate amount, colour, whether it followed sex, and any pelvic pain can make a medical history more precise. For women using HRT, dates of missed doses, regimen changes and expected withdrawal bleeds add useful context.

A postmenopausal bleeding pattern only becomes readable when episodes, associated symptoms and HRT changes are logged consistently over weeks. This is the kind of pattern Tulsy is built to surface.

Sources: The Guardian, Medical Xpress.

This content is for informational and educational purposes only. It is not intended to diagnose, treat, cure, or prevent any disease, and should not replace advice from a qualified healthcare professional.